Paeds SAQs · allergy-and-immunology
Vaccination of immunocompromised children — formative SAQs
Formative SAQs on classifying the immune defect, sorting each vaccine into live-attenuated versus inactivated, timing doses to the intensity of immunosuppression, and verifying serology — so a live vaccine is never given before a combined T-cell defect is excluded.
On this page
Study tools
Target exams
SAQ 1 (10 marks)
A four-month-old boy born overseas, now in Australia, is due for his routine immunisations. There is no newborn severe combined immunodeficiency (SCID) screening result on file. His maternal uncle died in infancy. He has persistent oral thrush and has crossed two weight centiles downward. His mother asks whether he can have his usual needles today. [1] [5]
a) State the single most important safety decision you must make before any vaccine is given today, and the specific group of vaccines that is at risk. (2 marks) [1]
b) List four features in this vignette that justify withholding live vaccines and investigating further. (2 marks) [5]
c) Name the live-attenuated vaccines that must be withheld today, and the test that confirms or excludes a combined T-cell defect. (3 marks) [1] [2]
d) Outline the management of the inactivated vaccines in this infant while the defect is being characterised, and the role of the household. (3 marks) [2]
References4ShowHide
- [1]Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis, 2014.PMID 24421306
- [2]National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2011.PMID 21293327
- [5]Gennery AR. Severe combined immunodeficiency: newborn screening and the BCG vaccination. Arch Dis Child, 2022.PMID 35973752
- [8]Hudspeth MP, et al. Post-hematopoietic stem cell transplant immunization practices in the Pediatric Blood and Marrow Transplant Consortium. Pediatr Blood Cancer, 2010.PMID 20135703